Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $27.05 USD
Change Today +0.71 / 2.70%
Volume 93.3K
GHDX On Other Exchanges
Symbol
Exchange
NASDAQ GS
Berlin
As of 2:16 PM 07/31/15 All times are local (Market data is delayed by at least 15 minutes).

genomic health inc (GHDX) Snapshot

Open
$26.50
Previous Close
$26.34
Day High
$27.19
Day Low
$26.03
52 Week High
10/31/14 - $37.74
52 Week Low
08/7/14 - $25.06
Market Cap
872.7M
Average Volume 10 Days
134.6K
EPS TTM
$-0.85
Shares Outstanding
32.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for GENOMIC HEALTH INC (GHDX)

genomic health inc (GHDX) Related Businessweek News

View More BusinessWeek News

genomic health inc (GHDX) Details

Genomic Health, Inc., a healthcare company, provides actionable genomic information to personalize cancer treatment decisions in the United States and internationally. It develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, allowing physicians and patients to make individualized treatment decisions. The company offers the Oncotype DX invasive breast cancer test that is used for early stage invasive breast cancer patients to predict the likelihood of breast cancer recurrence and chemotherapy benefit. It also provides the Oncotype DX colon cancer test, which is used to predict the likelihood of colon cancer recurrence in patients with stage II disease, as well as for use in patients with stage III disease treated with oxaliplatin-containing adjuvant therapy. In addition, the company provides the Oncotype DX tests for patients with ductal carcinoma in situ, a pre-invasive form of breast cancer; and Oncotype DX prostate cancer test, which provides a genomic prostate score to predict disease aggressiveness in men with low risk disease, as well as used to enhance treatment decisions for prostate cancer patients in conjunction with the Gleason score or tumor grading. Genomic Health, Inc. was founded in 2000 and is based in Redwood City, California.

752 Employees
Last Reported Date: 03/12/15
Founded in 2000

genomic health inc (GHDX) Top Compensated Officers

Chairman, Chief Executive Officer, President ...
Total Annual Compensation: $660.0K
Co-Founder and Chief Scientific Officer
Total Annual Compensation: $475.0K
Chief Financial Officer, Chief Operating Offi...
Total Annual Compensation: $500.0K
Compensation as of Fiscal Year 2014.

genomic health inc (GHDX) Key Developments

Urology Practice Publishes Genomic Health Inc.'s Results from the Second Clinical Utility Study of the Oncotype DX® Prostate Cancer Test

Genomic Health Inc. announced that Urology Practice published results from the second clinical utility study of the Oncotype DX® prostate cancer test, showing that incorporation of the test's Genomic Prostate Score (GPS) in treatment planning resulted in greater recommendations and acceptance of active surveillance as initial management of prostate cancer in low and low-intermediate risk patients. The multi-center study included 211 patients from 10 sites across the United States. The review of patient charts showed a relative increase of 56% in use of active surveillance in patients who received their Oncotype DX GPS compared to patients from the same practices with similar risk factors who were not tested. Additionally, the results showed an increase in physician recommendation of active surveillance that was consistent with a previous prospective clinical study published earlier this year. Together, the two published clinical utility studies demonstrate that use of Oncotype DX changes both treatment recommendations and actual treatment received, resulting in greater recommendation and adoption of active surveillance. The Oncotype DX® portfolio of breast, colon and prostate cancer tests applies advanced genomic science to reveal the unique biology of a tumor in order to optimize cancer treatment decisions. The Oncotype DX prostate cancer test identifies which clinically low-risk patients are eligible for active surveillance, as well as those who may benefit from immediate treatment by predicting disease aggressiveness.

Genomic Health, Inc. Announces Breast Cancer Research and Treatment Published Results from Oncotype DX DCIS Score Study

Genomic Health Inc. announced that Breast Cancer Research and Treatment published results from a second large clinical validation study of Oncotype DX in patients with stage 0 breast cancer, also known as DCIS (ductal carcinoma in situ). The population-based study, conducted by the Ontario DCIS Study Group, reconfirmed that the Oncotype DX DCIS Score is a strong predictor of local recurrence (p<0.001), which could be either invasive breast cancer or DCIS. Based on a population-based cohort of 828 DCIS tumor samples collected between 1994 and 2003 in Canada, the primary analysis focused on 571 patients who were treated with breast-conserving surgery alone and had clear margins. The newly published results of the study identified that the majority of studied DCIS patients (62%) were low risk based on the tumor biology revealed by the Oncotype DX DCIS Score. The remaining cases had an intermediate-risk or high-risk score, and these patients experienced a higher risk of local recurrence. These findings are consistent with those of the original ECOG-ACRIN Cancer Research Group clinical validation study, which demonstrated that the DCIS Score quantified the 10-year risk of local recurrence beyond clinical factors such as tumor size and grade.

Genomic Health Presents Positive Proof-of-Concept Data for Bladder Cancer Liquid Biopsy Test

Genomic Health Inc. announced positive results from a liquid biopsy proof-of-concept study demonstrating its ability to more conveniently detect disease recurrence with a level of accuracy comparable to cystoscopy, an invasive procedure for surveillance of early-stage bladder cancer. These results support Genomic Health's development of a urine test that may offer physicians and patients a non-invasive alternative for physicians to monitor patients' bladder cancer. Early-stage bladder cancer is estimated to recur in 10 to 15% of patients in the first year and in more than half of patients over time. Currently, bladder cancer surveillance is repeated at frequent intervals via a cystoscopy, a procedure that inserts an instrument equipped with a camera and light to look at the inside of the bladder. By measuring multiple target tumor-specific biomarkers using Genomic Health's liquid biopsy platform, the study demonstrated a negative predictive value for high-risk recurrence at that time of 95%, which means that if a patient's results are negative, there is a 95% chance that he or she has not had a recurrence at that time. These new results suggest that use of this urine-based liquid biopsy test would be expected to optimize surveillance and reduce the number of invasive procedures.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GHDX:US $27.05 USD +0.71

GHDX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Alliance HealthCare Services Inc $14.76 USD +0.99
Enzo Biochem Inc $3.00 USD -0.02
Foundation Medicine Inc $20.17 USD -2.13
NanoString Technologies Inc $15.52 USD +0.34
NeoGenomics Inc $6.16 USD +0.11
View Industry Companies
 

Industry Analysis

GHDX

Industry Average

Valuation GHDX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 3.1x
Price/Book 5.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 2.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GENOMIC HEALTH INC, please visit www.genomichealth.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.